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The discovery of C9orf72 mutations as the most common genetic cause of amyotrophic lateral sclerosis
(ALS) and frontotemporal dementia (FTD) has awakened a surge of interest in deciphering how muta-
tions in this mysterious gene cause disease and what can be done to stop it. C9orf72 harbors a hex-
anucleotide repeat, GGGGCC, in a non-coding region of the gene and a massive expansion of this repeat
causes ALS, FTD, or both (FTD/ALS). Many questions lie ahead. What does this gene normally do? What is
the consequence of an enormous GGGGCC repeat expansion on that gene's function? Could that hex-
anucleotide repeat expansion have additional pathological actions unrelated to C9orf72 function? There
has been tremendous progress on all fronts in the quest to deﬁne how C9orf72 mutations cause disease.
Many new experimental models have been constructed and unleashed in powerful genetic screens.
Studies in mouse and human patient samples, including iPS-derived neurons, have provided un-
precedented insights into pathogenic mechanisms. Three major hypotheses have emerged and are still
being hotly debated in the ﬁeld. These include (1) loss of function owing to decrease in the abundance of
C9orf72 protein and its ability to carryout its still unknown cellular role; (2) RNA toxicity from bidir-
ectionally transcribed sense (GGGGCC) and antisense (GGCCCC) transcripts that accumulate in RNA foci
and might sequester critical RNA-binding proteins; (3) proteotoxicity from dipeptide repeat proteins
produced by an unconventional form of translation from the expanded nucleotide repeats. Here we
review the evidence in favor and against each of these three hypotheses. We also suggest additional
experiments and considerations that we propose will help clarify which mechanism(s) are most im-
portant for driving disease and therefore most critical for considering during the development of ther-
apeutic interventions.
This article is part of a Special Issue entitled SI:RNA Metabolism in Disease.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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The recent discovery of a mutation in the C9orf72 gene as the
most common genetic cause of FTD and ALS (c9FTD/ALS) has
opened up many new and exciting areas of investigation in the
quest to understand neurodegenerative disease mechanisms and
to develop effective disease-modifying strategies. The C9orf72
gene contains a polymorphic hexanucleotide repeat, GGGGCC, lo-
cated in an intron. The repeat tract length in unaffected in-
dividuals, although variable, is typically between ﬁve and ten re-
peats and almost always fewer than 23 repeats (DeJesus-Hernan-
dez et al., 2011). In c9FTD/ALS cases, the hexanucleotide repeat
tract is expanded to hundreds or even thousands of repeats (De-
Jesus-Hernandez et al., 2011; Renton et al., 2011). This mutation
can now explain 40% of familial ALS and 5–10% of sporadic
cases (Renton et al., 2014). Hence, the major contribution of this
mutation to sporadic and inherited ALS and FTD has initiated in-
tense interest in deﬁning the mechanism by which C9orf72
GGGGCC repeat expansions cause neurodegeneration (Ling et al.,
2013).
There are currently three major hypotheses to explain howFig. 1. C9orf72 mutations: three proposed pathomechanisms. (A) The C9orf72 gene harb
gene. Large expansions of this nucleotide repeat cause c9FTD/ALS. There are currently th
(B) The large GGGGCC repeat expansion could cause a downregulation in C9orf72 gene e
and a loss of C9orf72's function. (C) RNA transcripts harboring C9orf72 repeat expansio
mulation of nuclear or cytoplasmic foci of GGGGCC RNA as well as the antisense GGCCCC
including splicing factors, leading to defects in pre-mRNA splicing by an RNA toxicity me
form of translation to generate a series of dipeptide repeat proteins, which accumulate
dipeptide repeat protein toxicity. Figure adapted from Ling et al. (2013).such repeat expansions could be pathogenic (Fig. 1). First, the
presence of an enormous GGGGCC repeat expansion could cause a
downregulation in C9orf72 gene expression, leading to a loss of
C9orf72's still undeﬁned normal cellular function (Fig. 1A). Indeed,
there is evidence that the presence of this repeat expansion leads
to a decrease in C9orf72 expression (DeJesus-Hernandez et al.,
2011). Second, an RNA-mediated toxicity mechanism could con-
tribute to disease (Fig. 1B). Cells harboring C9orf72 repeat expan-
sions, including patient brain and spinal cord neurons, contain
prominent nuclear foci of GGGGCC RNA (DeJesus-Hernandez et al.,
2011) as well as the antisense GGCCCC RNA (Gendron et al., 2013),
which could cause the sequestration of essential RNA-binding
proteins, including splicing factors, leading to defects in pre-mRNA
splicing (Gendron et al., 2014). Third, it has emerged that sense
and antisense repeat RNAs are substrates for an unconventional
form of translation to generate a series of dipeptide repeat pro-
teins, which accumulate in the brain and spinal cord of C9orf72
mutation carriers and may themselves be what is driving neuro-
degeneration (Fig. 1C).
These three proposed mechanisms are not completely mutually
exclusive, but deﬁning the major disease mechanism will beors a polymorphic hexanucleotide (GGGGCC) repeat in a non-coding region of the
ree major hypotheses to explain how such repeat expansions could be pathogenic.
xpression by interfering with transcription, leading to a decrease in C9orf72 protein
ns are produced by both sense and antisense transcription, resulting in the accu-
RNA, which could cause the sequestration of essential RNA-binding proteins (RBP),
chanism. (D) Sense and antisense repeat RNAs are substrates for an unconventional
in the brain and spinal cord of C9orf72 mutation carriers and may cause disease by
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For example, antisense oligonucleotide approaches to target the
repeat expansion (i.e., targeting mechanisms 2 and 3 above) are
being pursued and anticipated to enter clinical trials in humans in
the coming years. However, the success of these trials depends on
there not being a major requirement for C9orf72's normal function
because antisense approaches will lower levels of C9orf72 ex-
pression (unless they can be engineered to speciﬁcally target the
mutant allele (or speciﬁc RNA isoforms). Even if selectivity can be
achieved, could haploinsufﬁciency contribute to disease? Several
recent studies have provided evidence either in support or in
opposition to each of the three proposed mechanisms. Here, we
provide a review of the evidence in favor and against each of the
three hypotheses and we propose additional experiments and
analyses to further test each hypothesis and help clarify the role of
C9orf72 mutations in ALS and FTD pathogenesis.2. Mechanism 1: loss of function
Genetic discoveries can provide insight into molecular and
cellular pathways that open up new areas for mechanistic studies.
For example, the identiﬁcation of mutations in the RNA-binding
proteins TDP-43 and FUS/TLS immediately focused attention on
RNA metabolism as an important disease mechanism in ALS (La-
gier-Tourenne and Cleveland, 2009) and spurred research into RNA
processing alterations in ALS, ways to mitigate it, and potential
roles for additional RNA-binding proteins. Likewise, mutations in
VCP, UBQLN2, SQSTM1, and OPTN quickly focused attention on
cellular protein quality control pathways. But C9orf72 mutations
were puzzling because they were located in a non-coding region of
an uncharacterized human gene (literally, the seventy-second
open reading frame on chromosome 9). Nevertheless, efforts were
initiated to characterize the function of C9orf72 and to test the
hypothesis that loss of this function contributes to disease.
2.1. Evidence for C9orf72 loss of function
The C9orf72 gene is transcribed as three distinct transcript
variants. In variants 1 and 3 the expanded GGGGCC repeat is lo-
cated in an intron between two alternatively spliced exons,
whereas in variant 2 the repeat is located in the promoter region.
Initial reports of the C9orf72 hexanucleotide repeat expansion as a
cause of FTD/ALS included evidence of decreased C9orf72 variant
2 transcript levels in cells from mutation carriers (DeJesus-Her-
nandez et al., 2011; Gijselinck et al., 2012). This decrease in C9orf72
expression could cause disease by haploinsufﬁciency, if expression
of the wild type allele is not sufﬁcient to produce enough func-
tional C9orf72 protein. Other reports have suggested that the ex-
panded GGGGCC repeats might also interfere with the transcrip-
tion or splicing of the other variants (Mori et al., 2013a; Sareen et
al., 2013; Haeusler et al., 2014). Further studies have demonstrated
decreased expression levels of C9orf72 in iPS neurons and brain
from c9FTD/ALS patients (Almeida et al., 2013; Belzil et al., 2013;
Donnelly et al., 2013; Tran et al., 2015; Waite et al., 2014), whereas
others have provided evidence that speciﬁc C9orf72 transcript
variants are lowered whereas other ones are upregulated or sta-
bilized (Almeida et al., 2013; Mori et al., 2013a; Sareen et al., 2013).
How could the massive hexanucleotide expansion affect
C9orf72 expression levels? One hypothesis is that the G-quad-
ruplex and R-loop structures that the repeat can form (Fratta et al.,
2012; Reddy et al., 2013) could lead to abortive transcription of
C9orf72 (Haeusler et al., 2014). Alternatively, the GGGGCC repeat
could lead to hypermethylation of the C9orf72 locus. Methylation
of cytosine (C) in CpG islands is a mechanism to silence gene ex-
pression and other nucleotide repeat diseases, such as Friedrichataxia and fragile X mental retardation syndrome, are associated
with repeat-dependent hypermethylation and silencing of gene
expression (He and Todd, 2011). The large increase in CpG dinu-
cleotides, by virtue of the GGGGCC expansion, could provide many
more CpG islands as substrates for hypermethylation. Indeed,
using bisulﬁte sequencing, a method to directly detect CpG me-
thylation, the C9orf72 locus was hypermethylated in some C9orf72
mutation carriers (Xi et al., 2013). In addition to CpG methylation,
histone methylation of lysine residues is another epigenetic
modiﬁcation that can alter gene expression. Trimethylation of
histones H3 and H4 at the C9orf72 locus was detected in the blood
of C9orf72 mutation carriers (Belzil et al., 2013), providing another
mechanism to explain how this mutation could lead to decreases
in C9orf72 expression levels. Intuitively, it would seem that hy-
permethylation of C9orf72 would be deleterious, since it would
lead to a decrease in expression of C9orf72 and indeed one report
provides evidence that hypermethylation levels correlate with
shorter disease duration (Xi et al., 2013). However, other studies
have provided conﬂicting evidence and suggest that hy-
permethylation of the mutant C9orf72 allele might actually be
protective (Liu et al., 2014; McMillan et al., 2015; Russ et al., 2015).
The above results show that expression levels of C9orf72 are
reduced in a mutant dependent manner but they do not address
the physiological consequences of lowering C9orf72. Initial studies
of C9orf72 loss of function in vivo have been performed in model
organisms. A null mutation in the C. elegans C9orf72 orthologue
resulted in motor neuron degeneration and age-dependent deﬁcits
in motility. These mutants were also hypersensitive to environ-
mental stress induced neurodegeneration (Therrien et al., 2013).
Studies of C9orf72 function have also been performed in ver-
tebrates. There is a single C9orf72 orthologue, zC9orf72, present in
zebraﬁsh, which is 76% identical to the human protein (Ciura et al.,
2013). To lower levels of zC9orf72, zebraﬁsh embryos were in-
jected with three different morpholino antisense oligonucleotides
designed to block either the translation or splicing of zC9orf72.
These oligonucleotides are like nucleic acids but with important
chemical modiﬁcations, which increase their stability and make
them resistant to cellular nucleases and allow them to evade the
innate immune system. As negative controls, embryos were in-
jected with morpholino oligonucleotides designed against
zC9orf72 but which harbored ﬁve nucleotide mismatches to block
effective binding to the zC9orf72 mRNA. The oligonucleotides tar-
geting zC9orf72 resulted in shortened motor axons and defects in
axonal arborization in developing larvae. In addition to the axonal
phenotypes, targeting zC9orf72 levels elicited motor deﬁcits (re-
duction in both spontaneous swimming and escape swimming in
response to a light touch). These phenotypes could be rescued by
co-injecting mRNA encoding human C9orf72. Together, these re-
sults provided the ﬁrst in vivo evidence that loss of C9orf72
function could impair motor neuron function. If these results are
validated and extended, the zebraﬁsh model could be a powerful
platform for drug screening and to identify genetic modiﬁers.
Importantly, phenotypes obtained using morpholino oligonucleo-
tides in zebraﬁsh should be interpreted with caution, since off-
target effects, developmental delays, and other non-speciﬁc effects
could confound results (Gerety and Wilkinson, 2011). Genome
editing using CRISPR/Cas9 works robustly in animal models, in-
cluding zebraﬁsh, and can be used to engineer stable loss of
function mutations in the zC9orf72 gene (Hruscha et al., 2013). On
the other hand, phenotypic differences between genetic mutations
and gene knockdowns have been observed in zebraﬁsh (Rossi
et al., 2015). Thus, a combination of both approaches, together
with the appropriate positive and negative controls, will be im-
portant in assessing the requirement for C9orf72 function in
zebraﬁsh.
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In contrast to the results in C. elegans and zebraﬁsh, studies in
mouse have so far not supported a role for C9orf72 loss of function
as a cause of FTD/ALS. Administering antisense oligonucleotides
(ASOs) targeting mouse C9orf72 by stereotactic in-
tracerebroventricular (ICV) injection reduced C9orf72 mRNA levels
to 30-40% of control levels in the spinal cord and brain (Lagier-
Tourenne et al., 2013). This effect seemed long-lived and C9orf72
levels remained lowered even several months after the initial ASO
injection. C9orf72 depletion in these mice was well tolerated and
did not result in any behavioral or motor impairments. Cyto-
plasmic aggregation of ubiquitinated TDP-43 is the hallmark pa-
thological feature of FTD and ALS, including c9FTD/ALS. TDP-43
remained nuclear in brain and spinal cord sections and ubiquiti-
nated aggregates were not detected in mice with C9orf72 deple-
tion (Lagier-Tourenne et al., 2013). Thus, reducing C9orf72 levels
by over 50% in the nervous system for several months does not
result in neuropathological or behavioral phenotypes.
Another way to lower levels of C9orf72 in mouse is by gene
knockout. A conditional allele of C9orf72 was generated using the
Cre/loxP system. These mice were crossed to Nestin-Cre mice,
which express Cre recombinase in neurons and glia starting at
E10.5 and continuing into adulthood (Tronche et al., 1999). Cre-
mediated inactivation of C9orf72 in neurons and glia did not cause
deﬁcits in motor neuron numbers or in motor function, including
motor performance and grip strength (Koppers et al., 2015).
Hallmark ALS pathologies, including ubiquitinated TDP-43 ag-
gregates and gliosis were not detected either. There was no effect
on survival even after 24 months. Thus, in two different mouse
models, loss of C9orf72 function is not sufﬁcient to cause neuro-
degeneration and FTD/ALS-related phenotypes.
Two studies of human c9FTD/ALS have provided evidence ar-
guing against a loss of function disease mechanism. First, if hex-
anucleotide repeat expansion mutations in C9orf72 cause FTD/ALS
by a loss of function mechanism then other ways to disable
C9orf72 function could also be a cause of disease. However, an
analysis of the C9orf72 gene in several hundred ALS patients did
not identify deleterious mutations in the coding region of C9orf72
(including nonsense and frameshift mutations) (Harms et al.,
2013). Second, since heterozygous C9orf72mutation is sufﬁcient to
cause FTD/ALS, homozygous mutations might be predicted to
cause a more severe form of the disease or even a different clinical
presentation. However, an analysis of a patient homozygous for
the C9orf72 hexanucleotide repeat expansion revealed severe
clinical and pathological features that were in the normal disease
spectrum seen in heterozygous patients (Fratta et al., 2013). These
two studies, while certainly not deﬁnitive, are not consistent with
a loss-of-function mechanism.
Finally, studies in patient cells have provided somewhat of a
formal test for the loss-of-function vs. gain-of-function hy-
potheses. Several studies have used RNA proﬁling to characterize
gene expression changes associated with C9orf72mutations. These
studies have included ﬁbroblasts (Lagier-Tourenne et al., 2013),
iPS-derived neurons (Donnelly et al., 2013), iPS-derived motor
neurons (Sareen et al., 2013), and human brain (Prudencio et al.,
2015). Each study uncovered a mutant-speciﬁc RNA signature (i.e.,
present in C9orf72 mutant carriers but not healthy controls), albeit
different from one cell type to the next. If these alterations in gene
expression were caused by a loss of C9orf72 function, then low-
ering levels of C9orf72 (e.g., by targeting expression with ASOs)
would be predicted to either worsen or have no effect on the RNA
signature. However, the studies in iPS neurons and the iPS-motor
neurons revealed that targeting C9orf72 with ASOs actually im-
proved the signature rather than worsening it (Donnelly et al.,
2013; Sareen et al., 2013). Further, lowering C9orf72 in control cellsdid not recapitulate the RNA signature (Lagier-Tourenne et al.;
Sareen et al.). These results are not consistent with C9orf72 mu-
tations causing a loss of function.
2.3. Experiments to further test C9orf72 loss of function
Lowering levels of C9orf72 in C. elegans and zebraﬁsh appears
deleterious, whereas conditional inactivation of the gene speciﬁ-
cally in motor neurons and glia in mouse does not affect motor
neuron function or survival. Several additional studies will be
useful to help resolve these discrepancies (Fig. 2). The nestin-Cre
deletion of murine C9orf72 may not have removed enough of the
gene or in all of the right cells and tissues. Indeed, both human
C9orf72 and the mouse homolog (3110043O21Rik) are expressed
most highly in microglia and macrophages in the brain (Zhang
et al., 2014a; Zhang et al., 2016a), thus it will be important to
consider potential non-cell-autonomous mechanisms of neuro-
degeneration (e.g., by using additional Cre driver lines to delete
C9orf72 from microglia).
A germline knockout of C9orf72 would allow for the analysis of
heterozygous and homozygous mutant animals constitutively
lacking C9orf72 expression. Mice have been generated in which the
β-galactosidase gene replaces exons 2–6 of one of the C9orf72 al-
leles (Suzuki et al., 2013). Two very recent studies have used gene
targeting to generate homozygous mutant mice (Fig. 2A) and ex-
tensively analyzed them for any effects on survival and cognitive
or motor behavioral impairments (Atanasio et al., 2016; O'Rourke
et al., 2016). These mice did not develop motor neuron disease but
instead developed splenomegaly and several other peripheral
pathologies, including marked expansion of myeloid cells and
deﬁcits in immune responses and microglial function (Atanasio
et al., 2016; O'Rourke et al., 2016). The neuroinﬂammation seen in
these mice is reminiscent of that in human patient tissue. Thus,
while these data suggest that loss of C9orf72 function per se is
unlikely sufﬁcient to cause motor neuron disease, its requirement
for proper microglia function could suggest a possible way that its
loss could contribute to disease progression, similar to what is
seen in mouse models of familial ALS caused by SOD1 mutations
(Boillee et al., 2006; Ilieva et al., 2009).
Another formal test of loss- vs. gain-of-function involves the
use of C9orf72 knockout mice and some of the recently described
viral-mediated and BAC transgenic c9FTD/ALS models (Chew et al.,
2015; O'Rourke et al., 2015; Peters et al., 2015). These models
employ expression of human C9orf72 transgenes harboring various
GGGGCC repeat lengths either via adeno-associated virus medi-
ated somatic transgenesis (Chew et al., 2015) or in transgenic mice
generated from a bacterial artiﬁcial chromosomes (BAC) that ex-
presses a fragment of human C9orf72 containing an expanded
hexanucleotide repeat (Peters et al., 2015) or the full length
C9orf72 gene harboring an expanded repeat (O'Rourke et al., 2015).
These mice exhibit various phenotypes and pathological features
reminiscent of c9FTD/ALS (Chew et al., 2015; O'Rourke et al., 2015;
Peters et al., 2015). Breeding these mice to C9orf72 knockout mice
(heterozygous and homozygous) or injecting the C9orf72 trans-
gene into the central nervous system of the knockout animals will
test if disease features are or are not accelerated by the reduction
of wild type C9orf72 (Fig. 2B,C). If lowering levels of C9orf72 has no
effect on the phenotypes of human C9orf72 transgenic mice it
would argue directly against the hypothesis that reduced C9orf72
function contributes to c9FTD/ALS. Similar approaches have been
used to support a gain-of-function toxicity mechanism caused by
SOD1 mutations in familial ALS (Bruijn et al., 1998).
The ASO and RNA signature experiments described above,
which we used to argue against a loss-of-function mechanism,
could be extended one step further. If C9orf72 mutations cause
disease by a loss-of-function then increasing levels of C9orf72
Fig. 2. Additional experiments to test C9orf72 loss of function. (A) Mice have been generated in which the β-galactosidase gene replaces exons 2–6 of one of the C9orf72
alleles (Suzuki et al., 2013). These mice could be intercrossed to generate homozygous mutant mice (Atanasio et al., 2016; O'Rourke et al., 2016) and, together with their
heterozygous littermates, extensively analyzed for any effects on pathological phenotypes, survival and cognitive or motor behavioral impairments. (B) Crossing transgenic
mice containing a human BAC with a fragment of the C9orf72 locus harboring 500 GGGGCC repeats (e.g., Peters et al., 2015) to the C9orf72 knockout mice will test if disease
is accelerated by reducing wild type C9orf72 function. (C) Injecting the C9orf72 transgene (Chew et al., 2015) into the central nervous system of C9orf72 WT,þ/ , or /
animals will test if disease features are accelerated by the reduction of wild type C9orf72. (D) iPS derived neurons from c9FTD/ALS patients have been reported to exhibit
phenotypic differences from control neurons, including glutamate excitotoxicity, sensitivity to ER stress, and alterations in electrical activity. If these phenotypes are due to
loss of C9orf72 function, then increasing C9orf72 levels should mitigate them and lowering C9orf72 levels should worsen them. (E) C9orf72 may function as a guanine
nucleotide exchange factor (GEF) to regulate Rab GTPase activity. Rabs orchestrate multiple steps of membrane trafﬁcking within cells and it will be important to deﬁne
which Rab and thus which trafﬁcking step C9orf72 regulates.
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regulate C9orf72 expression levels (e.g., by transfecting expression
constructs) could be used to test this hypothesis in cell lines from
C9orf72 mutation carriers (Fig. 2D). If lowering C9orf72 levels in
these cell lines (Donnelly et al., 2013; Sareen et al., 2013) does not
make things worse and increasing C9orf72 levels does not make
things better, it would argue against a loss-of-function
mechanism.
The normal function of C9orf72 still remains poorly understood
and experiments to deﬁne this function will facilitate the study of
how alterations in that function might contribute to disease.
C9orf72 protein has homology to the Differentially Expressed in
Normal and Neoplasia (DENN) protein family, which function as
guanine nucleotide exchange factors (GEFs) to regulate Rab GTPase
activity (Levine et al., 2013; Zhang et al., 2012). Rab GTPases act as
molecular switches to orchestrate multiple steps of membranetrafﬁcking within cells (Yoshimura et al., 2010). It will be im-
portant to deﬁne which Rab(s) C9orf72 regulates since this will
provide insight into the particular trafﬁcking step and cellular lo-
cation (e.g., endosomes, lysosomes, Golgi, etc.) where it likely
functions (Fig. 2E). Assays to measure these trafﬁcking steps in
cells from c9FTD/ALS patients will help to test for C9orf72 loss of
function effects.3. Mechanism 2: RNA toxicity
A second way that the C9orf72 hexanucleotide repeat expan-
sion could cause disease is by a gain of RNA toxicity mechanism.
The initial descriptions of the mutation included evidence that
RNA foci containing the GGGGCC repeat accumulated in the brain
and spinal cord of c9FTD/ALS patients (DeJesus-Hernandez et al.,
A.D. Gitler, H. Tsuiji / Brain Research 1647 (2016) 19–29242011). With analogy to other nucleotide repeat expansion diseases
in which repeat-containing RNA foci accumulate, such as in myo-
tonic dystrophy, it was postulated that these GGGGCC RNA foci
could act as kind of landing pads for RNA-binding proteins and
splicing factors, sequestering them away from their normal func-
tion. Adding to the complexity of the proposed RNA toxicity me-
chanism, it was subsequently discovered that the antisense
GGCCCC repeat RNA was also transcribed from the C9orf72 hex-
anucleotide repeat and that these antisense RNAs accumulated in
distinct foci in c9FTD/ALS patients. Thus, a different suite of RNA-
binding proteins, which could bind and be sequestered by the
antisense foci was now sought. The race was on to identify these
RNA-binding proteins and to determine if and how their loss of
function contributes to disease.
3.1. Evidence for RNA toxicity
The striking appearance of GGGGCC sense and GGCCCC anti-
sense foci in the cells of patients with C9orf72 expansions (DeJe-
sus-Hernandez et al., 2011; Gendron et al., 2013; Lagier-Tourenne
et al., 2013; Mori et al., 2013a; Zu et al., 2013)
provided an attractive pathogenic mechanism: RNA-binding
proteins and splicing factors that recognized GGGGCC and GGCCCC
binding sites would be sequestered into these foci, disrupting their
normal function. This RNA toxicity mechanism is what underlies
myotonic dystrophy type 1 (DM1) and other microsatellite repeat
expansion diseases (Echeverria and Cooper, 2012). DM1 is caused
by a CTG repeat expansion in the 3'UTR of the DMPK gene (Ata-
nasio et al., 2016; Brook et al., 1992). The transcribed repeat ex-
pansion (CUG) accumulates as nuclear RNA foci in DM1 patients
(Davis et al., 1997; Taneja et al., 1995) and causes alterations in
RNA processing, including alternative splicing (Lin et al., 2006).
The RNA-binding protein muscleblind (MBNL) is sequestered in
the CUG-repeat containing foci in DM1 models and in DM1 pa-
tients (Fardaei et al., 2001; Jiang et al., 2004; Mankodi et al., 2001;
Miller et al., 2000). Importantly, upregulation of MBNL was sufﬁ-
cient to rescue phenotypes in a ﬂy DM1 model (de Haro et al.,
2006) and Mbnl knockout mice exhibited the same phenotype and
RNA processing changes seen in DM1. Taken together, there is
compelling evidence that DM1 is caused by an RNA toxicity me-
chanism, owing to sequestration of the MBNL RNA-binding pro-
tein. Indeed, DM1 discoveries have been paradigmatic for how
repeat expansion diseases could be caused by RNA toxicity
(Echeverria and Cooper, 2012).
When it was discovered that a repeat expansion is the most
common cause of ALS and FTD, an RNA-toxicity mechanism was
immediately considered and efforts were launched to ﬁnd the
“muscleblind” type of RNA-binding protein that would be se-
questered by GGGGCC or GGCCCC repeat foci. Many RNA-binding
proteins have been proposed to be sequestered by these repeats
but there still remains disagreement about which one, if any, is
critical for disease. These include SRSF2, hnRNP H1/F, ALYREF,
hnRNPA3, hnRNPA1, hnRNP-H, nucleolin, Pur-α, ASF/SF2, ADARB2,
and RanGAP1 (Donnelly et al., 2013; Haeusler et al., 2014; Lee
et al., 2013; Mori et al., 2013b; Reddy et al., 2013; Sareen et al.,
2013; Xu et al., 2013; Zhang et al., 2015; Cooper-Knock et al., 2014).
Future studies along the lines of those described above for DM1,
will be needed to determine if loss of function of any of these RNA-
binding proteins produces the same molecular alterations caused
by C9orf72 mutations and if upregulating their levels reverses
these phenotypes.
The RNA toxicity mechanism need not be limited to the nu-
cleus. Indeed, RNA foci have been detected in the cytoplasm of
ﬁbroblasts from C9orf72 mutation carriers (Lagier-Tourenne et al.,
2013; Sareen et al., 2013; Donnelly et al., 2013). Furthermore, a
combination of iPS-derived neurons from patients harboringC9orf72 mutations, studies in primary rodent neurons, and ex-
periments in Drosophila has demonstrated that GGGGCC repeat
RNA localizes distally within neurites where it associates with ri-
bonucleoprotein transport granules and interferes with local
translation (Schweizer Burguete et al., 2015).
3.2. Evidence against RNA toxicity
Because both RNA foci and dipeptide repeat proteins (DPRs) are
produced form C9orf72 expansions, it has been difﬁcult to de-
termine the relative contributions of each to pathogenesis. Two
recent experiments in model organisms have provided strong
evidence against the RNA toxicity mechanism. Several Drosophila
models have been generated to study the impact of expression of
C9orf72 GGGGCC repeats (Freibaum et al., 2015; Mizielinska et al.,
2014; Schweizer Burguete et al., 2015; Tran et al., 2015; Xu et al.,
2013; Zhang et al., 2015). Transgenic ﬂy lines can express the ex-
panded repeat in a tissue-speciﬁc manner (e.g., just the eye, only
in motor neurons, throughout the nervous system, etc.). Expres-
sion of GGGGCC repeats in ﬂies produces RNA foci and DPRs
(Freibaum et al., 2015; Mizielinska et al., 2014; Tran et al., 2015).
The ﬁrst experiment, by the Isaacs and Partridge groups cleverly
used Drosophila to disentangle potential contributions from the
C9orf72 repeat RNA and those of the DPRs (Mizielinska et al.,
2014). They generated two different ﬂy lines, each containing a
long GGGGCC repeat. One of the lines had a pure GGGGCC repeat
but for the other one they engineered it to contain regular inter-
ruptions with Stop codons to prevent it from being translated.
Both pure and interrupted repeats were expressed well and
formed RNA foci, however the interrupted one could not be
translated to form DPRs whereas the pure one could be a substrate
for RAN translation. Expression of pure repeats caused toxicity and
early lethality whereas the interrupted ones had no effect (Mi-
zielinska et al., 2014). These experiments provide evidence that
the GGGGCC repeats can cause toxicity in vivo through the pro-
duction of RAN translation products and not from the RNA alone.
A second experiment in Drosophila also argues against an RNA
toxicity mechanism and provides important new information
(Tran et al., 2015). The authors generated ﬂies with a transgene
harboring 160 GGGGCC repeats embedded within an intron. This
transgene was expressed, and spliced, and the GGGGCC repeat
formed many sense RNA foci in the nucleus. But there was no
neurodegeneration, in contrast to ﬂies produced by other labs (e.g.,
(Mizielinska et al., 2014)). A key difference between the Tran et al.
ﬂies and the Mizielinska et al. ones is the presence of the repeat
within the intron. The ﬂies in the Mizielinska et al. paper are made
to express the GGGGCC expansion in the context of an mRNA with
a 3'UTR, which allows it to be efﬁciently exported to the cyto-
plasm. This leads to the production of high levels of DPRs and
causes neurodegeneration. The ﬂies made by Tran et al. express
the repeat from within an intron, have high levels of sense RNA
foci in the nucleus, low levels of RAN translation, and no neuro-
degeneration. This means that accumulation of sense RNA foci in
the nucleus is not sufﬁcient to drive neurodegeneration in this ﬂy
model. The authors′ C9orf72 intron ﬂy model does not seem to
produce antisense RNA foci, which appears to be an important
feature of c9FTD/ALS (Cooper-Knock et al., 2015). Before we can
conclude that RNA foci in the nucleus do not contribute to neu-
rodegeneration, it will be important in the future to test the effect
of a similar level of antisense RNA transcripts in the ﬂy model.
3.3. Experiments to further test RNA toxicity
A parsimonious explanation for the ﬁndings from the two
Drosophila experiments described above is that pathologies seen
in the ﬂy C9orf72 models are due in large part (if not mostly) to
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in human cells and mouse remains to be determined. Several at-
tempts have been made to model C9orf72 mutations in mouse.
Bacterial artiﬁcial chromosomes (BAC) harboring various frag-
ments (Peters et al., 2015) or the full-length (O'Rourke et al., 2015)
human C9orf72 locus containing GGGGCC repeat expansions have
been generated. All of these mice recapitulate pathological fea-
tures, especially sense and antisense RNA foci and DPR production
(O'Rourke et al., 2015; Peters et al., 2015). However, these mice do
not seem to recapitulate the neurodegenerative disease features
seen in ALS and FTLD, although future studies to analyze con-
tributions of strain background and other factors are needed.
Another approach to model c9FTD/ALS in mouse was at-
tempted by Petrucelli and colleagues (Chew et al., 2015). They
used adeno-associated virus (AAV) to deliver a construct contain-
ing 66 repeats of GGGGCC (disease-range) or 2 repeats (negative
control). They administered these viruses by in-
tracerebroventricular injection into P0 mouse pups and waited for
6 months before performing a battery of behavioral and patholo-
gical analyses on these mice. This mouse model recapitulates the
cardinal features seen in human disease, including the accumu-
lation of RNA foci transcribed from the sense strand of the
GGGGCC repeat, production of RAN translation products (GP, GA,
GR) from the sense strand, neuronal loss and astrogliosis, andFig. 3. Additional experiments to test C9orf72 RNA toxicity. (A) Drosophila has been us
proteins (Mizielinska et al., 2014). Flies expressing a GGGGCC expanded repeat produ
phenotypes (e.g., rough eye). Engineering stop codons into the GGGGCC transgene m
phenotypes. (B) The new viral vector transgenic mouse model (Chew et al., 2015) could b
towards neurodegenerative phenotypes. Constructs could be generated that have Stop co
but preserve RNA foci formation. These mice could be assessed for pathological featurebehavioral and locomotor impairments (Chew et al., 2015). Strik-
ingly, these mice also exhibit robust TDP-43 pathology, a key
feature of c9FTD/ALS, not recapitulated in the BAC models
(O'Rourke et al., 2015; Peters et al., 2015). Given the ease and re-
producibility of this viral vector model, it can now be used, in a
way similar to the ﬂy experiments, to test relative roles of RNA and
DPRs towards neurodegenerative phenotypes. Constructs could be
generated that have Stop codons interrupting the repeats or
ﬂanking the repeats, in order to prevent translation but preserve
RNA foci formation (Fig. 3A). Future iterations of the viral vector
approach could also employ cell type speciﬁc promoters to express
the repeats in speciﬁc cell types (e.g., glia vs. neurons).4. Mechanism 3: dipeptide repeat protein toxicity
A third potential mechanism has emerged based on the ﬁnding
that the bidirectionally transcribed pathogenic repeat expansion
can be translated, even in the absence of an ATG start codon and
even though it is located in a non-coding region of C9orf72 (Ash
et al., 2013; Mori et al., 2013c; Zu et al., 2013). RAN (repeat-asso-
ciated non-ATG) translation, originally discovered by Ranum and
colleagues to occur in spinocerebellar ataxia type 8 (SCA8) and
DM1, which are caused by nucleotide repeat expansions (Zu et al.,ed to disentangle the contributions of C9orf72 RNA toxicity and dipeptide repeat
ce RNA foci and dipeptide repeat proteins (DPR), and exhibit neurodegenerative
aintains RNA foci but abolishes DPR production, and mitigates the degenerative
e used in a way similar to the ﬂy experiments, to test relative roles of RNA and DPRs
dons interrupting the repeats or ﬂanking the repeats, in order to prevent translation
s (TDP-43, RNA foci, DPRs) as well as neurodegeneration and cognitive deﬁcits.
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pansion diseases, including Fragile X tremor ataxia syndrome
(Todd et al., 2013), Huntington disease (Banez-Coronel et al., 2015)
and now c9FTD/ALS (Ash et al., 2013; Mori et al., 2013c; Zu et al.,
2013). This unconventional translation occurs in all reading frames
and results in the production of six dipeptide repeat proteins in
c9FTD/ALS: glycine-alanine (GA) and glycine-arginine (GR) from
sense GGGGCC transcripts, proline-arginine (PR) and proline-ala-
nine (PA) from antisense GGCCCC transcripts, and glycine-proline
(GP) from both sense and antisense transcripts. These dipeptide
repeat proteins (DPRs) are themselves aggregation-prone and ac-
cumulate throughout the central nervous system (Ash et al., 2013;
Gendron et al., 2013; Mori et al., 2013a; Mori et al., 2013c; Zu et al.,
2013). Are these DPRs benign bystanders or do they contribute to
neurodegeneration? And if they are toxic, are certain DPRs more
toxic than others? What are the cellular pathways that DPRs affect
and how do these impairments contribute to disease?
4.1. Evidence for dipeptide repeat protein toxicity
There is evidence that RAN translation products are compo-
nents of pathology in c9FTD/ALS (Ash et al., 2013; Gendron et al.,
2013; Mori et al., 2013a; Mori et al., 2013c; Zu et al., 2013). Moving
from pathology to potentially pathogenesis, several groups re-
ported experiments demonstrating that C9orf72 DPRs are toxic
and can cause neurodegeneration (Kwon et al., 2014; May et al.,
2014; Mizielinska et al., 2014; Wen et al., 2014; Yamakawa et al.,
2014; Zhang et al., 2014b; Zu et al., 2013; Yang, 2015). For instance,
the Petrucelli group has reported that expression of GA proteins in
the absence of RNA foci in primary neurons leads to impaired
proteasome activity, induction of endoplasmic reticulum stress,
and neurotoxicity in the absence of foci formation (Zhang et al.,
2014b). GA-induced neurotoxicity has also been associated with
loss of Unc119 function (May et al., 2014). GA has the ability to
form toxic amyloids and may even be able to spread from cell to
cell in a prion-like manner (Chang et al., 2016). Transgenic mice
generated to produce abundant GA pathology exhibit neurode-
generation and behavioral deﬁcits, possibly because of sequestra-
tion of HR23 proteins, which are involved in proteasomal de-
gradation (Zhang et al., 2016b). Other experiments have focused
attention on the arginine-rich DPRs (GR and PR). The addition of
recombinant PR or GR polymers to HeLa cells or human astrocytes
caused numerous RNA processing alterations and toxicity (Kwon
et al., 2014). The DPRs were able to rapidly enter the nucleus and
localize to nucleoli (sites of rRNA processing). Expression of PR
repeats within human motor neurons was also toxic (Wen et al.,
2014). GR and PR were also toxic in vivo because expressing 50
repeats of GR or PR caused toxicity and early lethality in Drosophila
(Mizielinska et al., 2014; Wen et al., 2014). Thus, in model systems
and cell culture, DPRs are sufﬁcient to cause toxicity. Whether this
is directly related to pathologies seen in human disease is still
unresolved.
A series of recent papers has implicated nucleocytoplasmic
transport impairments caused by C9orf72 mutations ((Boeynaems
et al., 2016; Freibaum et al., 2015; Jovicic et al., 2015; Zhang et al.,
2015) and reviewed in Fox and Tibbetts (2015) and van Blitterswijk
and Rademakers (2015)). Transport of RNA and protein cargos to
and from the nucleus is a highly regulated fundamental cellular
process (Burns and Wente, 2012). Defects in nucleocytoplasmic
transport could explain how TDP-43 and potentially other RNA-
binding proteins might accumulate in the cytoplasm in c9FTD/ALS.
Whereas all four groups agree on the cellular defect and re-
markably converged on the same pathway using vastly different
approaches and models, there is disagreement over the cause of
the defect. Zhang et al. say it's the sense RNA that is toxic, Frei-
baum et al. say that their phenotypes can be caused by toxic RNAs,DPRs, or some combination of both, and Jovičić et al. and Boey-
naems et al. say it's the DPRs that are causing the defects. The
Zhang et al. and Freibaum et al. studies use systems that produce
both RNA and DPRs, whereas the experiments by Jovičić et al. and
Boeynaems et al. use models, yeast and Drosophila, respectively,
which only express DPRs. Given this, the fact that all groups
identiﬁed the same types of genes involved in nucleocytoplasmic
transport as modiﬁers of C9orf72 phenotypes, suggests that the
defects in these models were likely caused by the DPRs. Moreover,
the studies by Tran et al., also using Drosophila, suggests that the
DPRs are responsible for the neurodegenerative phenotypes and
the RNA foci are, if anything, actually protective (Tran et al., 2015).
4.2. Evidence against dipeptide repeat protein toxicity
The experimental data in model systems demonstrate that
DPRs can be toxic but they do not prove that these are what drive
disease in humans. If DPRs are major drivers of neurodegeneration
in human c9FTD/ALS then a prediction is that one or more of the
DPRs should accumulate at high levels in the most affected regions
of the central nervous system. And perhaps the abundance of DPR
pathology should correlate with disease severity. However, several
studies of postmortem samples from C9orf72 mutation carriers
have so far mostly failed to correlate the abundance and locali-
zation of DPR pathology with neurodegeneration and clinical
phenotypes (Davidson et al., 2014; Mackenzie et al., 2014; Mack-
enzie et al., 2015; Schludi et al., 2015), although one study did
identify a correlation between GP levels and cognitive perfor-
mance (Gendron et al., 2015). In terms of relative abundance, it
seems that GA- and GP-positive inclusions are the most abundant
with GR being less abundant, and the PA and PR DPRs produced by
RAN translation of the antisense transcript being exceptionally
rare (Mackenzie et al., 2015).
Thus, there appears to be a disconnect between the striking
toxicities elicited by some of the DPRs in model systems and cell
culture and the apparent lack of clinicopathological evidence by
analysis of human postmortem samples. One interpretation is that
DPRs are not the major pathomechanisms associated with C9orf72
mutations (Mackenzie et al., 2015). But could some of the DPRs
that are difﬁcult to detect in postmortem analysis be so highly
toxic (e.g., PR) that they do not accumulate to high enough levels
before causing neuron death? Likewise, could DPRs exist in mul-
tiple conformations or strains, some toxic and others benign, as do
other neurodegenerative disease proteins (e.g., tau (Clavaguera
et al., 2013), αsyn (Guo et al., 2013), and Aβ (Aguzzi and Gitler,
2013; Lu et al., 2013)) and, if so, are the existing antibodies used to
detect DPR pathology only detecting certain conformations but not
other potentially more toxic ones?
4.3. Experiments to further test dipeptide repeat protein toxicity
The ultimate test of DPR toxicity as a mechanism in c9FTD/ALS
will require a way to speciﬁcally block RAN translation (with ge-
netic or chemical approaches), without affecting the sequence or
structure of the repeat. This will require a detailed understanding
of RAN translation mechanisms. What are the regulators and other
machinery that recognize extended repeat sequences and can
these be targeted to speciﬁcally inhibit RAN translation? The de-
velopment of speciﬁc RAN translation inhibitors will allow all of
these hypotheses to be tested in cell lines that express the C9orf72
repeat expansion (sense and antisense) in the context of the en-
dogenous location (Fig. 4A).
To resolve the apparent disconnect between data from cell
culture and model systems with that from histopathological ex-
amination of postmortem samples, imaging modalities to detect
DPRs in the brain of living C9orf72 mutation carriers would
Fig. 4. Additional experiments to test C9orf72 dipeptide repeat protein toxicity. (A) To speciﬁcally block RAN translation will require elucidating RAN translation mechanisms
and identifying RAN translation-speciﬁc regulators. These putative regulators will be new targets for the development of small molecule inhibitors to speciﬁcally inhibit RAN
translation. (B) The development of positron emission tomography (PET) ligands to detect DPR pathology in vivo would allow longitudinal studies of C9orf72 mutation
carriers to help resolve the role of DPRs in disease pathogenesis and to eventually be used in clinical trial settings to assess efﬁcacy of candidate therapeutics.
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preferentially bind amyloid ﬁbrils have been used as positron
emission tomography (PET) ligands, enabling in vivo imaging of
amyloid pathology (Mitsis et al., 2014). The development of similar
molecular beacons to detect DPR pathology in vivo would allow
longitudinal studies of C9orf72 mutation carriers to help resolve
the role of DPRs in disease pathogenesis and to eventually be used
in clinical trial settings to assess efﬁcacy of candidate therapeutics.
Meanwhile, powerful and highly sensitive immunoassays are
currently being developed to detect DPRs in blood or cerebrospinal
ﬂuid (CSF) as a way to measure DPR levels in human patients at
early and late stages of disease progression (Su et al., 2014).5. Concluding remarks
The discovery ﬁve years ago of C9orf72 mutations as the most
common cause of ALS and FTD (DeJesus-Hernandez et al., 2011;
Renton et al., 2011) has revolutionized the ALS and FTD research
ﬁeld leading to many new and exciting model systems, hy-
potheses, and even proposed therapeutic strategies. Ultimately,
when it comes to therapies, it may actually not be important to
distinguish between RNA toxicity and DPRs, since therapies tar-
geting the C9orf72 mutation (e.g., ASOs) will affect both RNA and
protein (Donnelly et al., 2013; Lagier-Tourenne et al., 2013; Sareen
et al., 2013) and can be designed to not interfere with expression
of the wild type allele or to speciﬁcally target certain RNA isoforms
(Donnelly et al., 2013; Lagier-Tourenne et al., 2013; Sareen et al.,
2013). If haploinsufﬁciency plays an important role in the disease,then such C9orf72 lowering strategies may not be effective. Thus, it
is of high priority to fully deﬁne the cellular function of C9orf72
and rigorously test the impact of C9orf72 loss of function pheno-
types in mouse models and human patient-derived cells.
There are intense discussions about which of the three me-
chanisms causes disease and, as detailed above, there has been
compelling evidence in support of and against each of the pro-
posed mechanisms. It is important to consider that it is possible
(perhaps probable) that a combination of multiple mechanisms
may actually be what causes disease. For example, perhaps re-
duced levels or function of C9orf72 could sensitize neurons and
increase neuronal vulnerability to other facets of C9orf72 pathol-
ogy (e.g., RNA foci or DPRs). Looking forward, the ﬁeld now has a
powerful collection of model systems, experimental reagents, and
analysis methods in hand to further clarify pathogenic mechan-
isms and to eventually develop effective therapeutic strategies.Acknowledgments
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